acceptability and safety of treadmill training ‐ No intervention control group (co‐interventions were not similar in both groups) Number of adverse events and drop‐outs · people with Parkinson's disease
1 finding from 1 review
Improved IBDQ at week 8 · people with active UC
Interferon‐B‐1a showed no clear difference in improved IBDQ at week 8 compared with placebo (moderate certainty).
1 finding from 1 review
IBDQ at week 8 · people with active UC
1 finding from 1 review
QoL · people with active UC
1 finding from 1 review
IBDQ at week 6 · people with active UC
1 finding from 1 review
Improved IBDQ at week 52 · people with active UC
Vedolizumab probably leads to higher improved IBDQ at week 6 compared with placebo (moderate certainty).
2 findings from 1 review
SF‐36 PCS at week 6 · people with active UC
1 finding from 1 review
Improved SF‐36 MCS at week 8 · people with active UC
1 finding from 1 review
Health‐related quality of life Multiple different outcome measures used EQ‐5D and EQ‐5D VAS (9 and 26 weeks) (Batterham 2014) SF‐36 PCS and MCS (8 and 26 weeks) (Elliott 2011) · people with active UC
1 finding from 1 review
SF‐36 MCS at week 52 · people with active UC
1 finding from 1 review
IBDQ at weeks 6 or 8 · people with active UC
TNF‐alpha antagonists leads to higher improved IBDQ at weeks 6 or 8 compared with placebo (high certainty).
2 findings from 1 review
QoL · people with active UC
1 finding from 1 review
Improved IBDQ at week 8 · people with active UC
Infliximab leads to higher improved IBDQ at week 8 compared with placebo (high certainty).
1 finding from 1 review
IBDQ at week 6 · people with active UC
1 finding from 1 review
EQ‐5D at week 6 · people with active UC
1 finding from 1 review
Health‐related quality of life · people with active UC
Infliximab probably leads to higher improved SF‐36 PCS at week 8 compared with placebo (moderate certainty).
1 finding from 1 review
Improved SF‐36 MCS at week 8 · people with active UC
Infliximab probably leads to higher improved SF‐36 MCS at week 8 compared with placebo (moderate certainty).
1 finding from 1 review
Improved IBDQ at week 8 · people with active UC
Adalimumab probably leads to higher improved IBDQ at week 8 compared with placebo (moderate certainty).
1 finding from 1 review
Improved IBDQ at week 52 · people with active UC
Adalimumab probably leads to higher improved IBDQ at week 52 compared with placebo (moderate certainty).
1 finding from 1 review
Live birth · women undergoing assisted reproduction
It is very uncertain whether testosterone changes live birth ‐ Testosterone vs estradiol + OCP compared with other active interventions (very low certainty).
2 findings from 1 review